DOP37: Noninvasive assessment of gut function using transcriptional recording sentinel cellsECCO'24 Stockholm 2024
DOP38: A rare KRT17+ population emerges from the epithelium in the inflamed intestinal mucosa of patients with Ulcerative ColitisECCO'24 Stockholm 2024
DOP39: Constructing butyrate-producing yeast as a cell-dependent treatment option for Inflammatory Bowel DiseaseECCO'24 Stockholm 2024
DOP40: Inflammatory Bowel Disease single cell atlas construction to enable cell type-specific target identificationECCO'24 Stockholm 2024
DOP41: Mucosal single-cell profiling of Crohn's-like disease of the pouch reveal unique pathogenesis and therapeutic targetsECCO'24 Stockholm 2024
DOP43: Histologic improvement, attenuation of inflammation and microbiome modulation by engineered high acetate producing Saccharomyces boulardii in DSS-induced colitisECCO'24 Stockholm 2024
DOP45: Blood-derived neutrophils give rise to differentially activated populations in the mucosa of active Inflammatory Bowel Disease patientsECCO'24 Stockholm 2024
DOP46: Tofacitinib for hospitalized acute severe Ulcerative Colitis – the TRIUMPH studyECCO'24 Stockholm 2024
DOP47: Characterisation of endoscopic improvement in Crohn’s Disease with upadacitinib treatmentECCO'24 Stockholm 2024
DOP48: Faecal microbiota transplantation in active Ulcerative Colitis: Key lessons from a randomized controlled trial halted for futilityECCO'24 Stockholm 2024
DOP49: Guselkumab improves health-related quality of life as measured by PROMIS-29 in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction studyECCO'24 Stockholm 2024
DOP50: PINPOINT: The epidemiology of paediatric-onset Inflammatory Bowel Disease in the United Kingdom – a prospective, national, cohort study.ECCO'24 Stockholm 2024
DOP51: Risk of kidney failure in patients with Inflammatory Bowel Disease undergoing colectomy: a nationwide cohort studyECCO'24 Stockholm 2024
DOP52: Guselkumab improves symptoms of fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 QUASAR induction study results at Week 12ECCO'24 Stockholm 2024
DOP53: Long-term Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn's Disease up to 3 Years of Treatment: Results From the FORTIFY Open-Label Long-term ExtensionECCO'24 Stockholm 2024
DOP54: Guselkumab and golimumab combination induction therapy in Ulcerative Colitis results in early local tissue healing that is sustained through guselkumab maintenance therapyECCO'24 Stockholm 2024
DOP55: High diagnostic accuracy of 4-probe methylation biomarkers in paediatric Inflammatory Bowel Disease by epigenome-wide analysisECCO'24 Stockholm 2024